Trial Profile
Phase II Study With PARP Inhibitor Veliparib (ABT-888) in Patients With Increased Risk of Homologous Recombination Deficiency to Determine the Value of an (Ex-vivo) RAD51 Assay as a Biomarker
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Veliparib (Primary)
- Indications Advanced breast cancer; Cancer; Ovarian cancer; Triple negative breast cancer
- Focus Biomarker; Therapeutic Use
- Acronyms REPAIR
- 01 Jul 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 09 May 2019 Planned initiation date changed from 1 Nov 2018 to 1 Nov 2019.
- 26 Apr 2018 Planned End Date changed from 1 Aug 2020 to 1 Nov 2020.